Is Allogene Therapeutics, Inc. (ALLO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 17.6% / 30% | 56.6% / 30% | 0.0% / 30% | 91604.55% / 5% | ✗ NOT HALAL |
| DJIM | 17.6% / 33% | 56.6% / 33% | 0.0% / 33% | 91604.55% / 5% | ✗ NOT HALAL |
| MSCI | 16.5% / 33% | 53.3% / 33% | 0.0% / 33% | 91604.55% / 5% | ✗ NOT HALAL |
| S&P | 17.6% / 33% | 56.6% / 33% | 0.0% / 33% | 91604.55% / 5% | ✗ NOT HALAL |
| FTSE | 16.5% / 33% | 53.3% / 33% | 0.0% / 50% | 91604.55% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -53.4% | |
| Return on Assets (ROA) | -26.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$149M |
| Free Cash Flow | -$150M |
| Total Debt | $83M |
| Debt-to-Equity | 28.5 |
| Current Ratio | 7.9 |
| Total Assets | $416M |
Price & Trading
| Last Close | $2.41 |
| 50-Day MA | $2.08 |
| 200-Day MA | $1.47 |
| Avg Volume | 5.6M |
| Beta | 0.5 |
|
52-Week Range
$0.86
| |
About Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Allogene Therapeutics, Inc. (ALLO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Allogene Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Allogene Therapeutics, Inc.'s debt ratio?
Allogene Therapeutics, Inc.'s debt ratio is 17.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 16.5%.
What are Allogene Therapeutics, Inc.'s key financial metrics?
Allogene Therapeutics, Inc. has a market capitalization of $551M. Return on equity stands at -53.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.